Lilly allies with gene-editing firm Seamless on hearing loss Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss

#Geneediting specialist #SeamlessTherapeutics has attracted its first major #pharmapartner, #EliLilly, with a $1.12 billion #alliance that will seek out therapies for #hearingloss.